N/A N=45 Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=134 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Severe Hepatic Veno-Occlusive Disease
Primary: Survival at Day+100 Following Hematopoietic Stem Cell Transplant — 38.2; 25.0 percentage of participants
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 2 N=235 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
Primary: Change From Baseline in MQC on Liver Biopsy at Week 96 — -0.5; 0.5; 0.0 percentage of MQC
Phase 3 N=1,206 Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Hepatic Veno-Occlusive Disease
Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy — 49.9 Percentage of participants alive
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 4 N=93 The SIM-SOF Trial for Hepatitis C
Chronic Hepatitis C
Primary: Proportion of Participants With Sustained Virologic Response 12 (SVR-12) — 54; 18 participants — p=.02
Phase 2 N=77 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
Primary: DB Phase: Change From Baseline In Serum Alkaline Phosphatase (ALP) — -105.05; -110.19; -26.76 U/L — p=0.0434
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Phase 3 N=196 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
Sickle Cell Anemia · Stroke
Primary: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct — 2.0; 4.8 infarct recurrence per 100 person years
N/A N=214 Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction
Sphincter of Oddi Dysfunction
Primary: Percentage of Participants With Success — 23; 37 percentage of paricipants with success — p=0.01
Phase 2 N=48 Pasireotide LAR in Severe Polycystic Liver Disease
Somatostatin Analogs · Polycystic Liver Disease · Autosomal Dominant Polycystic Kidney Disease
Primary: Change in Liver Volume — -3.36; 6.29 percentage of change — p=0.001
Phase 3 N=372 Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
Veno-occlusive Disease
Primary: Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC) — 66.8…
N/A N=7 Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 3 N=20 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
Cirrhosis · Congenital Heart Disease
Primary: Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE) — 5.69; 5.72; 5.02; 5.68 kPa
Phase 2 N=54 A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease
Sickle Cell Disease
Primary: Percentage of Group C Participants Who Achieved Complete Resolution of Vaso-occlusive Events (VOE-CR) — 87.5 percentage of participants
N/A N=74 Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis
Radiation Induced Fibrosis to the Head and Neck
Primary: Improvement in Neck Fibrosis — 13; 13 participants
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Phase 2 N=10 The Effect of Sorafenib on Portal Pressure
Clinically Significant Portal Hypertension
Primary: Patients With Change in HVPG From Baseline — 1; 1 participants
N/A N=21 SRL (Sirolimus) Withdrawal
Acute Rejection of Liver Transplant · Effects of Immunosuppressant Therapy
Primary: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology at 12 Months — 8 Participants
Phase 3 N=42 Octreotide in Severe Polycystic Liver Disease
Polycystic Kidney, Autosomal Dominant · Polycystic Liver Disease · Hepatomegaly
Primary: Percent Change in Liver Volume — -5.0; 0.9 percent change — p=0.048
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 2 N=20 Simvastatin (Zocor) Therapy in Sickle Cell Disease
Sickle Cell Disease
Primary: Change in Total Cholesterol Level — -16; -18; -18 mg/dL
Phase 2 N=91 Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
Jaundice, Neonatal · Hyperbilirubinemia, Neonatal
Primary: Total Serum Bilirubin (mg/dL) — 9.82; 9.97; 9.92; 8.48 mg/dL — p==0.0000021